12:00 AM
 | 
Nov 25, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Tecfidera dimethyl fumarate regulatory update

EMA's CHMP said Biogen Idec's multiple sclerosis drug Tecfidera dimethyl fumarate qualifies as a new active substance (NAS). In March, the committee recommended approval of an MAA for Tecfidera to treat adults with relapsing-remitting MS, but the recommendation did...

Read the full 172 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >